Physician profile
Paloma Alexander Ortiz Fernandez
NPI 1588309405
$10,049.07
in general payments reported to CMS, 2019-2025
17 companies · $742 in 2025
The $742 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $221 · 2022: $520 · 2023: $8,566 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,340 · Travel and Lodging: $3,029 · Food and Beverage: $1,755 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,340.00 |
| Travel and Lodging | $3,029.49 |
| Food and Beverage | $1,755.26 |
| Education | $183.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $7,742.77 | 2023-2025 | Nerlynx |
| Eli Lilly Export S.A. Puerto Rico Branch | $637.31 | 2021-2023 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $401.76 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $346.46 | 2022-2025 | Keytruda, Keytruda Qlex, Welireg |
| Genzyme Corporation | $222.83 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $117.87 | 2025 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $104.14 | 2025 | |
| Exelixis INC. | $99.00 | 2023 | |
| Lilly USA, LLC | $97.62 | 2022 | |
| Taiho Oncology, INC. | $93.16 | 2023-2025 | |
| Caris Mpi, INC. | $45.33 | 2025 | Mi Cancer Seek |
| Ipsen Biopharmaceuticals, INC | $43.47 | 2025 | Onivyde |
| Pharmaessentia USA Corporation | $24.53 | 2023 | Besremi |
| Tolmar Pharmaceuticals, INC. | $21.22 | 2022 | |
| Pfizer INC. | $18.73 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $18.57 | 2023 | Orserdu |
| Janssen Pharmaceuticals, INC | $14.30 | 2025 | Rybrevant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paloma Ortiz Fernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.